Study of Efficacy and Safety of Investigational Treatment in Patients With Hidradenitis Suppurativa

Summary

This is a randomized, double-blind, placebo-controlled, parallel-group phase 1b study to evaluate AT193 in approximately 44 participants with HS. The treatment period will be 8 weeks followed by a 2-week nontreatment follow-up. The primary objective of this study is to evaluate the safety and tolerability of AT193. The secondary objectives of this study are to evaluate the preliminary efficacy in the treatment of HS.

Timeline

Start

2021-11-23

Primary completion

2023-03-15

Completion

2023-03-15

Drugs

Indications